New drug combo aims to tame tough lung cancer
NCT ID NCT07465757
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel infusions in 21-day cycles, with doses increasing in later groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at stubborn lung cancer
- Could a hidden nerve condition be more common in lung cancer than we think?
- Can a gentler drug trio tame small cell lung cancer in older patients?
- Experimental combo aims to tackle Treatment-Resistant cancers
- New PET scan targets hidden lung cancer cells
- New drug THE-0504 enters human testing for tough cancers